Pharmaceutical Promotional Expenses Under the Corporate Tax Law
Introduction
Whether pharmaceutical promotional expenses may be taken into consideration as deductible expenses under the Corporate Tax Law No. 5520 (“CTL”) is significant in terms of the determination of commercial income. In this framework, establishing a causal link between such expenses and the generation and maintenance of corporate income is decisive for the deductibility of the relevant expenses. Particularly considering the scope and limits of promotional activities specific to the pharmaceutical sector, the status of such expenditures under tax legislation may become subject to discussions in practice. Therefore, the assessment of pharmaceutical promotional expenses within the framework of the provisions of the CTL is of critical importance both for the management of tax risks and compliance. In this respect, court decisions regarding the subject also serve as guidance in determining the limits of practice. As a matter of fact, court decisions assess the consideration of pharmaceutical promotional expenses as deductible expenses within the framework of whether such expenditures are related to the business, duly documented, and carried out in compliance with the legislation. In this context, this article will briefly address the relevant regulations and subsequently examine judicial decisions regarding the subject.
Definition of Pharmaceutical Promotion
The definition of pharmaceutical promotions carried out by pharmaceutical companies is regulated under the Regulation on Promotional Activities of Human Medicinal Products (“Regulation”), enacted pursuant to the Law No. 1262 on Pharmaceutical and Medical Preparations. Accordingly, pursuant to Article 4 of the Regulation, pharmaceutical promotion is defined as all informational activities to be carried out by authorization/license holders, or with the name, request, contribution, or support of authorization/license holders, regarding the medical-scientific characteristics of products to healthcare professionals; including the activities of product promotion representatives, advertisements in medical and professional books and journals, announcements made through direct mailing or other communication tools, scientific meetings and product promotion meetings, and similar activities. Furthermore, Article 5 of the Regulation regulates the scope of pharmaceutical promotional activities. Indeed, it is stipulated that the products covered under the Regulation shall include promotional activities directed at physicians, dentists, and pharmacists. Accordingly, promotional activities directed at healthcare professionals are carried out:
- using promotional materials directed at physicians, dentists, and pharmacists,
- by organizing or supporting scientific meetings and product promotion meetings,
- through visits made by product promotion representatives to physicians, dentists, and pharmacists.
Deductibility as Expense
An expense is essentially defined as decreases in the assets or increases in the liabilities of an enterprise arising from deliveries of goods or production, use of services, or other transactions related to the principal business activity during a specific period.
Furthermore, pursuant to Article 40/1 of the Income Tax Law No. 193 (“ITL”), general expenses incurred for the generation and maintenance of commercial income are among the deductible expenses in the determination of net income. In addition, the provision lists the deductible expenses in determining net income. Moreover, while Article 8/1 of the CTL regulates the expenses deductible from corporate income by corporate taxpayers, Article 11 of the CTL sets forth the non-deductible expenses in the determination of corporate income.
Therefore, for an expense to be deducted from revenues in determining the net amount of period income, (i) a causal link must exist between the expense and the generation or maintenance of income, and (ii) the expense must be incurred for the generation of income.[1]
Pharmaceutical Promotional Expenses
Based on the explanations above, as a rule, for any expenditure made by pharmaceutical companies to be taken into consideration as an expense, such expenditure must have been incurred within the scope of the company’s activities.
Although pharmaceutical promotional expenses may appear to fall within the activities of pharmaceutical companies, these expenses shall not be always accepted as deductible expenses. At this point, assessing judicial decisions shall be important in determining to what extent pharmaceutical promotional expenses may be considered as deductible expenses.
Decisions of the Council of State and Regional Administrative Courts Regarding Pharmaceutical Promotional Expenses
Whether pharmaceutical promotional expenses in the pharmaceutical sector may be considered as deductible expenses has long been controversial, and there is no uniform approach in judicial decisions:
1- The Decision of the 3rd Chamber of the Council of State dated 19.09.2025 and numbered Case No: 2023/8876, Decision No: 2025/3360
In the incident subject to this Decision[2], transportation, accommodation, and registration expenses of doctors and company employees attending scientifically themed congresses and symposiums were deducted from corporate income by the company engaged in pharmaceutical marketing activities, and the relevant value added taxes were also treated as deductible. The defendant administration, on the other hand, considered such expenses as non-deductible expenses (“NDE”) on the grounds that they could not be evaluated within the scope of the company’s activities, and accordingly made corporate tax and provisional tax assessments.
The court of first instance stated that considering the functioning of the pharmaceutical sector, congress and symposium expenses were in the nature of advertisement, promotion, and publicity expenses and that such expenses were necessary for the continuation of commercial activities. The Court further stated that participation expenses of healthcare professionals in scientific meetings could be supported under certain conditions within the scope of the Regulation. Since there was no determination indicating any violation of the provisions of the Regulation in the concrete case, it was decided to annul the disputed assessment.
The Regional Administrative Court, however, evaluated that scientific congresses were not organized directly for the purpose of pharmaceutical promotion but were scientific meetings bringing together professionals in a specific medical field. In this respect, it concluded that such expenses were not directly related to the generation and maintenance of commercial income and found the corporate tax and value added tax assessments lawful. Nevertheless, the provisional tax was cancelled on the grounds that provisional tax for which the offset period had expired could not be sought.
In its decision, the Council of State stated that in addition to expenses being incurred for the purpose of generating and maintaining commercial income, a causal link between the expense and the commercial activity must also exist. In this respect, the Council of State particularly considers the following issues:
- Promotional Regime in the Pharmaceutical Sector: Pursuant to the Regulation, promotion of pharmaceuticals to the public is prohibited and promotion is permitted only to healthcare professionals. Therefore, scientific meetings and product promotion meetings were considered among the principal promotional tools in the sector.
- Causal Link Between the Expenses and the Activity: It was stated that congress and symposium expenses were in the nature of advertisement, promotion, and publicity expenses, and that company employees attended such meetings to promote products, follow scientific developments, and obtain professional knowledge. Therefore, it was concluded that a causal link existed between the relevant expenses and the company’s activities.
- No Violation of the Conditions under the Regulation: It was emphasized that the administration had not established any determination indicating a violation of the conditions set forth under the relevant Regulation.
Based on the grounds, the Council of State concluded that there was no compliance with law in the corporate tax assessments made by considering congress and expenses as NDE and rendered a reversal decision in favor of the pharmaceutical company.
2- The Decision of the 1st Tax Litigation Chamber of the Istanbul Regional Administrative Court dated 30.01.2023 and numbered Case No: 2022/2522, Decision No: 2023/176
In the incident subject to this Decision[3], the tax inspection report issued regarding the plaintiff pharmaceutical company alleged that certain expenses related to medical congresses attended or organized by the plaintiff should be removed from costs on the grounds that they constituted NDE.
The court of first instance evaluated that medical congresses were directly related to marketing and sales activities for pharmaceutical companies. The Court stated that such expenses fell within the scope of general expenses incurred for the generation and maintenance of commercial income and that the provisions of the Regulation merely regulated the procedures and principles regarding the conduct of such activities. On these grounds, the case file was accepted.
In its assessment regarding congress expenses, the Regional Administrative Court particularly considered the following issues:
- Nature of Scientific Meetings: The Regional Administrative Court stated that the relevant organizations were not organized entirely for the purpose of pharmaceutical promotion but were scientific meetings bringing together professionals regarding certain medical subjects. Therefore, it concluded that the expenses could not be directly associated with pharmaceutical promotion.
- Participation of Company Employees: It was stated that the persons who may be sent to scientific meetings within the scope of the Regulation are healthcare professionals and that company employees could not be considered within this scope. Therefore, no unlawfulness was found in the non-acceptance of congress expenses incurred for company employees.
Based on the grounds, the Regional Administrative Court annulled the decision of the court of first instance and dismissed the case.
Conclusion
In recent judicial decisions, whether congress and symposium expenses incurred in the pharmaceutical sector may be taken into consideration has been assessed within the scope of the characteristics of the concrete case, the functioning of the sector, and the relevant legislative provisions. While the decisions acknowledge that scientific meetings constitute an important promotional tool in the pharmaceutical sector and that certain expenses incurred within this scope may be considered advertisement, promotion, and publicity expenses incurred for the generation and maintenance of commercial income, in some cases it is concluded that scientific meetings do not directly serve the purpose of product promotion and therefore expenses for which a sufficient causal link with the activity cannot be established may be considered as NDE.
- Yetkiner, Erkan: “Gelir ve Kurumlar Vergisi Kanununa Göre İlaç Tanıtım Giderlerinin Mahiyeti”, s.2.
- The Decision of the 3rd Chamber of the Council of State dated 19.09.2025 and numbered Case No: 2023/8876, Decision No: 2025/3360.
- The Decision of the 1st Tax Litigation Chamber of the Istanbul Regional Administrative Court dated 30.01.2023 and numbered Case No: 2022/2522, Decision No: 2023/176.
All rights of this article are reserved. This article may not be used, reproduced, copied, published, distributed, or otherwise disseminated without quotation or Erdem & Erdem Law Firm's written consent. Any content created without citing the resource or Erdem & Erdem Law Firm’s written consent is regularly tracked, and legal action will be taken in case of violation.
Other Contents
In tax law, the concept of the commerce of immovable property is of great importance for determining the applicability of tax exemptions that may come into play under certain conditions, particularly in the sale of immovable property…
Venture capital is defined as investing in areas where no one has previously dared to invest . In the guideline prepared by the Capital Markets Board (“CMB”), which has the authority to regulate and supervise the capital markets, venture capital is expressed as a form of financing that enables dynamic and creative...
The digitalization process in Turkish commercial life has gained momentum with the widespread adoption of practices that enable commercial ledgers to be kept electronically. In this context, the Communiqué on the Keeping of Non-Accounting Commercial Ledgers of Enterprises in Electronic Form (“Communiqué”)...
The share buyback by a joint stock company is regulated under Articles 379 to 389 of the Turkish Commercial Code No. 6102 (“TCC”). However, in cases where the company subsequently sells these repurchased shares, there is no specific provision in the tax legislation addressing whether the “participation exemption...
Through Articles 4, 33 and 34 of Law No. 7524 on the Amendment of Tax Laws and Certain Laws and Decree-Law No. 375 ("Law No. 7524"), by adding subparagraphs to Article 94 of the Income Tax Law No. 193 and Articles 15 and 30 of the Corporate Tax Law No. 5520, payments made by intermediary...
As a general rule, under Article 80 of the Repetitive Income Tax Law No. 193 ("ITL"), capital gains derived from the disposal of securities, except for exemptions, are subject to income tax as capital appreciation gains...
Article 2 of Law No. 7524 on the Amendment of Tax Laws and Certain Laws and Decree-Law No. 375 ("Law No. 7524") and the income tax exemption for the benefits provided to employees by issuing share certificates, which is regulated under Article 17 of Income Tax Law No. 193 ("ITL"), entered into force as of...
While tax systems introduce general regulations to prevent the abuse of laws, special regulations are introduced as tax security institutions within the scope of tax laws for situations where general regulations do not fulfill the expected function in practice...
It is known that legislative amendments have been made for the acquisition of Turkish citizenship by foreigners within the scope of the Turkish Citizenship Law No. 5901 in order to encourage the sale of residences and workplaces to foreigners...
Through its decision dated 30 November 2023 and No. E. 2023/105 K. 2023/208 ("Decision"), the Constitutional Court of the Republic of Türkiye ("Constitutional Court") annulled the regulation stating that inflation adjustment will not be made for 2021 as stipulated under Provisional Article 33 of Turkish Tax...
Law No. 7456 on Additional Motor Vehicle Tax for Compensation of Economic Losses Caused by the Earthquake on 6/2/2023 and on Amendments to Certain Laws and Decree-Law No. 375 (“Law No. 7456”) was published in the Official Gazette dated 15.07.2023 and No. 32249. Law No. 7456 introduced significant...
In order to determine the procedures and principles regarding the implementation of certain articles of the Misdemeanor Law No. 5326 (“Law”), which is the general procedural law for administrative fines, the Ministry of Treasury and Finance (“Revenue Administration”) has published the General...
Through Article 20 of Law No. 7440 on Restructuring of Certain Receivables and Amending Certain Laws (“Law No. 7440”), published in the Official Gazette dated 12 March 2023 and No. 32130, significant and new tax regulations regarding debt push down financing structure for merger transactions are introduced...
Provisional Article 32 was added to Banking Law numbered 5411 (“BL”) through Article 17 of the Law No. 7186 on Amendments to the Income Tax Law and Certain Laws ("Law No. 7186") in the Official Gazette on 19.07.2019. This law enables companies that are experiencing financial difficulties, but which are...
Law No. 7420 on the Amendment of Income Tax Law and Certain Laws and Decrees (“Law No. 7420“) which was published in the Official Gazette dated 09.11.2022 introduced important amendments and regulations in the tax legislation. The addition of Article 32/B, entitled "Taxation in Capital Decrease" to...
Free Zones are zones that are established to promote export-oriented investment and production, accelerate foreign direct investment and technology access, direct enterprises towards export, and develop international trade. There are many tax advantages provided to taxpayers operating in...
Through the promulgation of Law No. 7394 on the Amendments of Treasury-Owned Immovable Property Valuation and the Value Added Tax Law and on the Amendments of Certain Other Laws and Decrees, published in the Official Gazette dated 15 April 2022 and No. 31810, significant amendments...
In recent years, many new business models have emerged and traditional business models have changed greatly, within the increasing digitalization in the economy. Along with said change, challenges arose for taxing the international business income of...
Through the promulgation of the Law No. 7351, published in the Official Gazette dated 22.01.2022 and no. 31727, essential amendments are introduced to Turkish tax legislation. Apart from the tax amendments, a new provision has been added to...
Social media has emerged with the development of the digital world and internet technology and has greatly influenced the world today. One of the main categories of actors in social media is social media content producers. These people earn through social networks in...
Law No. 7326 on the Restructuring of Certain Receivables and Amendments to Certain Laws ("Law No. 7326") entered into force by being published in the Official Gazette dated 9 June 2021. In Law No. 7326, provisions regarding (i) the restructuring of finalized tax receivables, (ii) tax receivables that are not...
The 1990’s hold significant importance by means of the developments that took place in the global economy. During the transition to the second half of the 1900’s, the Federal Reserve increased interest rates, and the hot money flow changed its direction from East Asian countries to the West...